



Press Release

Aragen Signs Collaboration Agreement with Azurity Pharmaceuticals to Set up Dedicated Formulations Development Center

March 9, 2023; Hyderabad, India

Aragen Life Sciences Private Limited (“Aragen”), a global contract research, development, and manufacturing organization (CRDMO) announces a collaboration with Azurity Pharmaceuticals Inc, a US-based pharmaceutical company focused on developing innovative dose-forms and formulations of products to serve the needs of overlooked patients. The agreement is for a dedicated pharmaceuticals formulations development center at Aragen’s Hyderabad campus. The dedicated center will support the development of multiple products across a wide range of therapeutic areas.

Commenting on the collaboration, **Manni Kantipudi, CEO, Aragen Life Sciences**, said, *“We are delighted to partner with Azurity in setting up the dedicated formulations development center and look forward to building a longstanding relationship. Our scientists will work closely with Azurity’s global development team in developing innovative formulations for patients.”*

“Our partnership with Aragen adds additional capability and capacity to our development efforts, complementing the work at our established development center in Kansas City, USA. It will allow us to better serve overlooked patients by adding more scientists to our bench to develop medications at speed and scale,” said **Richard Blackburn, CEO, Azurity Pharmaceuticals**.

About Aragen: Aragen Life Sciences is a leading R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug development continuum to advance small and large-molecule programs. With more than 22 years of experience, the Company operates through a global network of six sites with a team of ~4500 employees and 450+ PhDs. Its expertise and experience have enabled over 400 customers (including 6 of the top 10 pharma companies globally) in advancing their research programs from early discovery through development and commercialization. Aragen’s innovative mindset, infrastructure, flexible business models, clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details.

About Azurity: Azurity Pharmaceuticals is a privately held pharmaceutical company that focuses on innovative products that meet the specific needs of overlooked patients. As an



industry leader in providing accessible, high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company's products currently span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients. For more information, visit www.azurity.com.

Media Contacts:

Aragen Life Sciences: Sandeep Nair, Sandeep.nair@aragen.com

Azurity: Samantha Cummis, media@azurity.com